Objective: Interruption of antiretroviral therapy (ART) in chronic HIV disease is associated with increased mortality, predicted by elevations in interleukin-6 (IL-6) and D-dimer. The effect of ART interruption in primary HIV-1 infection on these biomarkers is unknown.
Introduction
Untreated HIV infection is associated with systemic inflammation, which persists, to a lesser extent, with viral control on antiretroviral therapy (ART) [1, 2] . In the Strategies for Management of Antiretroviral Therapy (SMART) trial, in which individuals with chronic HIV infection were randomly allocated to interruption or continuation of ART, those interrupting treatment had higher risk of death compared to continuous therapy [3] . Baseline levels of inflammatory and pro-coagulatory biomarkers interleukin-6 (IL-6) and D-dimer were predictive of all-cause mortality. Interruption of ART was associated with significant rises in these biomarkers 4 weeks following treatment discontinuation [4] , providing a likely biological explanation for the adverse outcomes seen.
Whilst ART interruption in chronic HIV infection is no longer recommended, recent data from the VISCONTI study and others [5] [6] [7] reporting unexpected rates of sustained post-treatment viral control after discontinuing ART initiated in primary HIV infection (PHI) has led to interest in the use of early transient ART to achieve functional cure. Few data exist examining the effect of initiating ART in PHI and subsequently interrupting it on IL-6 and D-dimer. Using data from participants enrolled in the Short Pulse Anti-Retroviral Therapy At HIV Seroconversion (SPARTAC) trial, we examine the effect of transient ART commenced in PHI on these biomarkers.
Methods
Short Pulse Anti-Retroviral Therapy At HIV Seroconversion participants with defined PHI within a maximum of 6 months of seroconversion were randomly allocated to deferred therapy [standard of care (SoC)] -12-week (ART12) or 48-week ART (ART48) [8] . Plasma samples were taken at baseline (randomization; week 0) and weeks 12, 16, 48, 52, 60 and 108. We analysed stored samples from sites in Australia, Brazil, Italy and the United Kingdom, where HIV-RNA assays had a lower limit of detection of 50 copies/ml. Plasma IL-6 and D-dimer levels were measured using Quantikine HS600B IL-6 immunoassay (R&D Systems, Minneapolis, Minnesota, USA) and Innovance D-dimer (Siemens Healthcare Diagnostics, Tarrytown, New York, USA).
Changes in IL-6 and D-dimer levels from week 0 to week 12 were compared between participants who started ART and those who did not, using linear regression models in an as-treated analysis, adjusting for baseline values. We examined biomarker changes over this period by week 12 HIV-RNA level, categorized as below 50, 50 to less than 400 and at least 400 copies/ml, and also considering HIV-RNA as a continuous variable.
We compared biomarker levels 4 weeks after stopping ART with pre-ART levels using linear regression, restricting analysis to participants initiating and stopping ART at scheduled time-points, with below 50 copies/ml at ART stop. We also looked at changes from ART stop to 4 weeks later, and compared baseline to ART stop. We calculated areas under the biomarker-time curves (AUC) to week 108, adjusted for baseline values, and compared these across the three trial arms using an intention-totreat analysis.
For all analyses, values of both biomarkers were log 10transformed. For presentation of regression results, coefficients were exponentiated to obtain percentage differences.
To enable comparison between SPARTAC and the SMART trial, samples from 10 SPARTAC participants were shipped to the University of Vermont, where SMART biomarker evaluations took place. A chemiluminescent assay for IL-6 (R&D Systems Q6000B) and immunoturbidimetric assay for D-dimer (STA-R analyser; Stago, Parsipanny, New Jersey, USA) were used. Bland-Altman plots were generated to assess the level of agreement between measurements at SPARTAC and SMART laboratories.
Results
Samples were available for 200 of 299 (87%) eligible participants (72 SoC, 63 ART12 and 65 ART48). Of 128 randomized to ART, one did not initiate treatment. Of the remainder, all but one initiated therapy within 7 days, and 94% within 3 days of randomization.
Baseline characteristics
Participant characteristics and factors associated with IL-6 and D-dimer levels at baseline have previously been described [9] . Overall, 191 (96%) were male, median [inter-quartile range (IQR)] age was 34 years (29, 42) and median time from estimated seroconversion was 11 weeks [7, 14] . Median CD4 þ T-cell count and HIV-RNA levels were 559 (443, 700) cells/ml and 4.66 (3.84-5.25) log 10 copies/ml, respectively. Median (IQR) baseline IL-Interleukin-6 and D-dimer at week 12 Interleukin-6 and D-dimer values at week 12 were available for 172 and 164 participants, respectively, of which 57 and 56 were untreated. IL-6 levels at week 12 were similar to baseline levels for both treated and untreated participants, with mean [95% confidence interval (CI)] and percentage change from baseline of À0.09 (À0.15 to À0.04) log 10 pg/ml and À19.6% for those treated and À0.04 (À0.11 to þ0.04) log 10 pg/ml and À8.3% for those untreated (P ¼ 0.23), both adjusted for baseline levels. In contrast, D-dimer levels significantly dropped from baseline by week 12 for participants on ART, but increased for those not on ART, with À0.09 (À0.14 to À0.04) log 10 mg/l and À18.7% for treated, and þ0.10 (þ0.02 to þ0.17) log 10 mg/l and þ25.2% for untreated participants (P < 0.001).
Biomarker changes from baseline to week 12 are presented in Fig. 1 by treatment status and HIV-RNA levels for treated individuals. There was a suggestion of a greater decrease in IL-6 levels for those achieving lower HIV-RNA (continuous variable) at 12 weeks (P ¼ 0.072), but no such association for D-dimer levels (P ¼ 0.89).
Interleukin-6 and D-dimer 4 weeks after antiretroviral therapy stop
Of participants who stopped ART correctly and had biomarkers measured 4 weeks later, 70 (70%) achieved HIV-RNA below 50 copies/ml at ART stop. Four weeks after stopping, median (IQR) HIV-RNA for these participants was 3.63 (2.93, 4.47) log copies/ml.
Biomarker levels significantly increased from ART stop to 4 weeks later, with an overall mean change for IL-6 of þ0.09 log 10 pg/ml (95% CI þ0.003, þ0.17, P ¼ 0.044) (þ22% mean percentage on log 10 scale), and for D-dimer þ0.07 log 10 mg/l (95% CI þ0.003, þ0.14, P ¼ 0.041) (þ18% mean percentage on log 10 scale).
Overall, for treated individuals with HIV-RNA below 50 copies/ml at ART stop, biomarker levels 4 weeks after stopping were similar to pre-ART levels, with a mean difference of þ0.03 log 10 pg/ml (95% CI À0.07, þ0.13, P ¼ 0.53) for IL-6, and À0.05 log 10 mg/l (95% CI À0.12, þ0.03, P ¼ 0.20) for D-dimer ( Fig. 1 ).
Interleukin-6 and D-dimer over time by trial arm
Median biomarker levels over time are shown according to trial arm in Fig. 2 . Over 108 weeks follow-up, overall IL-6 AUC was À0.03 (95% CI À0.07, 0.02) log 10 pg/ml, with no difference between the three arms (P ¼ 0.53). In comparison, D-dimer AUC was significantly lower for ART12 (À0.11, 95% CI À0.20, À0.02) and ART48 (À0.13, 95% CI À0.23, À0.04) log 10 mg/l, respectively, compared to SoC (overall P ¼ 0.008).
Inter-laboratory variation
We found highly significant correlations between biomarkers measured in the SPARTAC and SMART laboratories (Pearson's correlation coefficient for log 10transformed values ¼ 0.97, P < 0.0001; and 0.77, P ¼ 0.014 for IL-6 and D-dimer, respectively). However, absolute values differed between the two assays for both biomarkers and were consistently higher for IL-6 and lower for D-dimer at the SMART laboratory compared to the SPARTAC laboratories (Appendix, http://links. lww.com/QAD/A685).
Discussion
The present study is the first to describe the effect of starting, and subsequently stopping, ART in PHI on two biomarkers associated with all-cause mortality. The reason why individuals start or defer ART in PHI may not be random, and may be driven by factors which themselves are linked to biomarker changes. The study design of random allocation to ART deferral, initiation and cessation avoids the bias that is unavoidable amongst many PHI cohort studies.
Initiation of ART within 6 months of seroconversion significantly reduced D-dimer levels after 12 weeks, but not IL-6 levels overall, in keeping with findings from the SMART study [10] . We found evidence of a greater reduction in IL-6 with lower HIV-RNA, suggesting that IL-6 levels drop only upon attainment of viral suppression, whereas the drop in D-dimer may be more immediate upon ART initiation. This finding is also in keeping with the SMART study, which demonstrated a significant decline in IL-6 and D-dimer amongst those achieving viral suppression by 6 months [10] . Of note, we were able to examine HIV-RNA categories below 50 and 50-400 copies/ml separately (in the SMART study, suppression was defined as <400 copies/ml) and found no evidence of an association between achieving 50-400 copies/ml at week 12 and a reduction in either biomarker. The reduction in IL-6 observed in the SMART study among those achieving less than 400 copies/ml may, therefore, be driven by those achieving less than 50 copies/ml.
Stopping ART in the SPARTAC study was associated with increase in both biomarkers 4 weeks after discontinuing therapy, lower for IL-6 than those experienced by SMART participants interrupting therapy (22 vs. 30%), but similar for D-dimer (18 vs. 16%) [4] . Median IL-6 level 4 weeks after ART cessation was 1.51 pg/ml in the SPARTAC study, which is lower than that seen in the SMART study [4] . However, we found consistently higher IL-6 levels at the SMART laboratory, compared to those measured on parallel samples from the same patient and time-point at the SPARTAC laboratory, demonstrating the need for caution when comparing biomarker results between studies, as results may be affected by the assay used, laboratory techniques or storage conditions. Absolute levels for D-dimer 4 weeks after stopping ART for SPARTAC participants were similar (median 0.32 mg/l) to SMART controls (0.26 mg/l) and substantially lower than in those who had died (0.49 mg/l) in the SMART study [4] . Given our finding of consistently lower Ddimer levels at the SMART laboratory, we may have underestimated the differences between biomarker levels in those initiating and then stopping ART in PHI compared to chronic infection. We have previously described lower HIV-RNA rebound following ART cessation initiated in PHI compared to chronic infection [11] , and theorize that this may also be true for biomarker rebound. As ART in PHI was restricted to a maximum of 48 weeks in the SPARTAC study, we cannot comment on whether ART of longer duration may positively impact on biomarker levels upon cessation.
Over 108-week follow-up, overall IL-6 levels were comparable across the three arms, whereas D-dimer was significantly lower for participants randomized to the two ART arms compared to SoC. This may, in part, be due to the lower viral set-point observed in participants receiving ART48 [8] , although no change in viral setpoint was seen amongst ART12 individuals, suggesting an alternative explanation. It is not possible to extrapolate from this analysis whether the observed reduction in D-dimer confers any clinical benefit.
In the SPARTAC study, in contrast to the SMART study, no significant clinical events were reported following cessation of therapy [8] . The use of ART in PHI may have several benefits in reducing viral reservoirs [12, 13] , preserving immunological function [8] , limiting long-term immunological damage [13] [14] [15] [16] and reducing onward HIV transmission [17] . Reports of long-term viral control following discontinuation of early treatment have led to renewed hopes for sustained clinical benefits in some individuals [5] . Our data provide evidence that treatment interruption following either 12 or 48 weeks therapy has no significant adverse effects on IL-6 and D-dimer levels up to 2 years after PHI compared to untreated individuals. While higher postseroconversion IL-6, but not D-dimer, predicts HIV disease progression [9] , the clinical significance of biomarker rebound following ART interruption in this setting remains uncertain. analyses. E.H., W.S. and K.P. wrote the first draft of the article. All authors contributed to subsequent drafts and approved the final version. J.W. was the Principle Investigator for the SPARTAC study.
